share_log

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder

Benzinga Real-time News ·  Jul 21, 2022 10:36
  • Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint. 
  • CIPD is a rare chronic autoimmune disease affecting the peripheral nervous system, resulting in progressive symmetric weakness and impaired sensory function in the arms and legs.
  • Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment. 
  • Also Read: Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years.
  • Analyses from ADVANCE-1 are ongoing, and the company anticipates disclosing additional data in an upcoming medical forum.
  • HYQVIA showed a favorable safety profile in topline analyses, further supporting its use as maintenance therapy for CIDP. 
  • Of the 62 patients treated with HYQVIA, most treatment-related adverse events were reported as mild or moderate. No new safety risks were reported with HYQVIA. 
  • The safety profile of HYQVIA in CIDP will be further supported by data from the ongoing ADVANCE-3 trial, an extension study with up to six years of follow-up data on some participants.
  • Price Action: TAK shares are up 0.52% at $14.56 during the market session on the last check Thursday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment